Hypolipidemic activity of 5-aryl-3-methylvaleric acid derivatives.
Several 5-aryl-3-methylvaleric acid derivatives have been shown to be more potent hypolipidemic agents than the previously reported 5-(4-biphenylyl)-3-methylvaleric acid (1). The most active compound in this series was 5-(4-phenylsulfonylphenyl)-3-methylvaleric acid (10) which lowered serum cholesterol levels 45% and serum triglyceride levels 60% in normal rats. Significant lowering of the serum triglyceride levels was the predominant effect noted with most of the compounds tested.
D000818:Animals; D002784:Cholesterol / Q000097:blood; D000960:Hypolipidemic Agents / Q000138:chemical synthesis*; D066298:In Vitro Techniques; D008055:Lipids / Q000096:biosynthesis; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051381:Rats; D013329:Structure-Activity Relationship; D014280:Triglycerides / Q000097:blood; D014631:Valerates / Q000138:chemical synthesis* / Q000494:pharmacology
D000960:Hypolipidemic Agents; D008055:Lipids; D014280:Triglycerides; D014631:Valerates; D002784:Cholesterol